de Jonghe F, Swinkels J, Tuynman-Qua H
Department of Psychiatry, University of Amsterdam, The Netherlands.
Pharmacopsychiatry. 1991 Jan;24(1):21-7. doi: 10.1055/s-2007-1014428.
In a six-week double-blind randomized trial, preceded by a one-week period of single-blind placebo treatment, the efficacy and the side-effects of fluvoxamine (100-300 mg/d) (n = 24) and maprotiline (50-150 mg/d) (n = 24) were compared in moderately depressed outpatients with DSM-III Major Depression (n = 22) or Dysthymic Disorder (n = 26). Efficacy was measured by means of the Hamilton Depression Rating Scale, the Zung Depression Selfrating Scale, and a Clinical Global Impression of Severity Scale. Side-effects were evaluated by an Adverse Event Inventory and a Psychosomatic Symptom Scale. A statistically significant improvement was achieved in both treatment groups but success rates were modest: in both groups, 29% of the patients achieved a clinically significant improvement after six weeks of treatment. After six weeks of treatment, no difference in efficacy was found between fluvoxamine and maprotiline. Nausea was the most common complaint in the fluvoxamine group, while in the maprotiline group, it was dry mouth and constipation. One maprotiline-treated patient developed a convulsive attack.
在一项为期六周的双盲随机试验中，试验前先进行为期一周的单盲安慰剂治疗，对24例服用氟伏沙明（100 - 300毫克/天）和24例服用马普替林（50 - 150毫克/天）的中度抑郁症门诊患者（其中22例患有DSM-III重度抑郁症，26例患有恶劣心境障碍）的疗效和副作用进行了比较。疗效通过汉密尔顿抑郁量表、zung抑郁自评量表和临床总体严重程度印象量表进行衡量。副作用通过不良事件清单和心身症状量表进行评估。两个治疗组均取得了统计学上的显著改善，但成功率不高：两组中，29%的患者在治疗六周后取得了临床上的显著改善。治疗六周后，氟伏沙明和马普替林在疗效上没有差异。恶心是氟伏沙明组最常见的主诉，而在马普替林组中，最常见的是口干和便秘。一名接受马普替林治疗的患者发生了惊厥发作。
